Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals

[1]  A. Schulga,et al.  Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. , 2019, Molecular pharmaceutics.

[2]  P. Geramifar,et al.  Design, preparation and biological evaluation of a 177Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors. , 2019, Bioorganic chemistry.

[3]  R. Y. Yakovlev,et al.  Radiopharmaceuticals Based on Alpha Emitters: Preparation, Properties, and Application , 2018, Physics of Atomic Nuclei.

[4]  E. N. Lebedenko,et al.  Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies , 2017, Molecular Biology.

[5]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[6]  K. Howard,et al.  Albumin-based drug delivery: harnessing nature to cure disease , 2016, Molecular and Cellular Therapies.

[7]  H. Jadvar,et al.  Targeted Radionuclide Therapy: Practical Applications and Future Prospects , 2016, Biomarkers in cancer.

[8]  P. Albertsson,et al.  The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond , 2013, Front. Oncol..

[9]  A. Plückthun,et al.  Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. , 2013, Structure.

[10]  Guy Georges,et al.  The emerging role of new protein scaffold-based agents for treatment of cancer. , 2013, Cancer genomics & proteomics.

[11]  S. M. Deyev,et al.  Modern Technologies for Creating Synthetic Antibodies for Clinical application , 2009, Acta naturae.

[12]  Vladimir Tolmachev,et al.  Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.

[13]  J. Carlsson,et al.  Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.

[14]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.